---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-006281"
form_type: "8-K"
ticker: "ADVB"
cik: "0001941029"
company_name: "Advanced Biomed Inc."
filed_at: "2026-01-21T23:59:59+00:00"
generated_at: "2026-05-16T09:21:25.560061+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Advanced Biomed faces Nasdaq delisting after failing minimum bid price; appeals with reverse split plan

## Summary
- Failed to regain minimum $1.00 bid price by Jan 14, 2026; Nasdaq notified delisting effective Jan 27, 2026.
- Company appealed on Jan 21, 2026, staying suspension pending Nasdaq hearings panel decision.
- Regain compliance plan includes reverse stock split approved Jan 12, 2026, effective on/after Feb 13, 2026.
- No assurance that panel will grant continued listing or that compliance will be achieved.

## SEC filing metadata
- accession: 0001213900-26-006281
- form_type: 8-K
- ticker: ADVB
- cik: 0001941029
- company_name: Advanced Biomed Inc.
- filed_at: 2026-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1941029/000121390026006281/0001213900-26-006281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1941029/000121390026006281/ea027358501-8k_advanced.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-006281
- JSON: https://secwatch.observer/filing/0001213900-26-006281.json
- Plain text: https://secwatch.observer/filing/0001213900-26-006281.txt

## Key facts
- Listing & Compliance Notices
  Advanced Biomed Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: January 16, 2026, the Staff notified the Company that its securities would be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 27, 2026, unless the Company requested an appeal of this determination by January 23, 2026 before a Hearings Panel (the “Panel”). On January 21, 2026, the Company appealed the Staff’s delisting determination by submitting a hearing request to the Panel, which stayed the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. The Company expects to present to the Pan
  evidence_url: https://www.sec.gov/Archives/edgar/data/1941029/000121390026006281/0001213900-26-006281-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.